Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | POLB | P06746 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 6/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.57 |
| ▸ | MEN1 | O00255 | 6/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22425113 | 0.82 | MAPT (0.62) | MAPTKDM4EPOLBRAB9AKMT2A | |
| SCHEMBL22425076 | 0.82 | MAPT (0.74) | MAPTKDM4ERAB9AKMT2AMEN1 | |
| SCHEMBL20777328 | 0.81 | MAPT (0.75) | MAPTKDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL22425250 | 0.80 | MAPT (0.65) | MAPTKDM4ERAB9AKMT2AMEN1 | |
| SCHEMBL24430209 | 0.79 | MAPT (1.00) | MAPTKDM4EPOLBRAB9AKMT2A | |
| SCHEMBL22425034 | 0.78 | MAPT (0.77) | MAPTKDM4EPOLBKMT2AMEN1 | |
| SCHEMBL20772662 | 0.77 | MAPT (0.69) | MAPTKDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL1276481 | 0.77 | KDM4E (0.82) | MAPTKDM4EPOLBRAB9AKMT2A | |
| SCHEMBL30393282 | 0.77 | KDM4E (0.82) | MAPTKDM4EPOLBRAB9AKMT2A | |
| SCHEMBL22425089 | 0.76 | KMT2A (0.66) | MAPTKDM4EPOLBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150099781-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-09 | — | — | US | disclosed |
| US-8969342-B2 | Compounds and methods for treating mammalian gastrointestinal microbial infections | BRANDEIS UNIVERSITY (US) | 2015-03-03 | — | — | US | disclosed |
| US-20120101096-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | University of Georgia Foundation, Inc. (US) | 2012-04-26 | — | — | US | disclosed |
| WO-2010108187-A2 | COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS | BRANDEIS UNIVERSITY (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101096-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | IMPDH1, IMPDH2, IMPA1 | MAPT 4129/4885KDM4E 1620/4885POLB 2033/4885 |
| US-20150099781-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | IMPDH1, IMPDH2, IMPA1 | MAPT 4129/4885KDM4E 1620/4885POLB 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.